Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights

Jan 09 2012

• By Bridget Silverman

Related Content

FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

Dec 01 2011

Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

Jan 01 2011

The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies

Feb 01 2011

Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?

Jan 02 2012

FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals

Nov 01 2011

FDA Sets A Fast Pace Of Novel Approvals In First Half, But That's Likely To Slow

Jul 01 2011

Related Companies

Novartis AG

GSK plc

Johnson & Johnson

Bristol Myers Squibb Company

AstraZeneca PLC

Merck & Co., Inc.

Pfizer Inc.

Roche Holding AG

Eli Lilly and Company

Boehringer Ingelheim GmbH

Bayer AG

Forest Laboratories, Inc.

Human Genome Sciences, Inc.

Additional Topics

Drug Approval Standards Innovation BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window